Skip to main content

and
  1. No Access

    Article

    Ex vivo dual gene therapy using human adipocytes secreting anti-HER2 antibody on HER2-positive xenograft tumor models

    Although targeted treatments against human epidermal growth factor receptor 2 (HER2) have improved survival in patients with metastatic HER2-positive breast cancer, long and repeated treatment is time-consumin...

    Ryotaro Teranaka, Hiroshi Fujimoto, Takahito Masuda, Masayuki Kuroda in Breast Cancer (2023)

  2. Article

    Open Access

    The impact of PIK3CA mutations and PTEN expression on the effect of neoadjuvant therapy for postmenopausal luminal breast cancer patients

    There is pressing needs to find the biomarker in the selection of neoadjuvant therapy in postmenopausal luminal breast cancer patients. We examined the hypothesis that PIK3CA mutations and low phosphatase and ten...

    Shouko Hayama, Rikiya Nakamura, Takayuki Ishige, Takafumi Sangai in BMC Cancer (2023)

  3. No Access

    Article

    Histological features of skin and subcutaneous tissue in patients with breast cancer who have received neoadjuvant chemotherapy and their relationship to post-treatment edema

    Lymphedema is a major complication of treatment for breast cancer. Although chemotherapy can cause lymphedema, there have been few reports about histological changes in skin and subcutaneous tissue after chemo...

    Ayako Nakagawa, Hiroshi Fujimoto, Takeshi Nagashima, Takafumi Sangai in Breast Cancer (2020)

  4. No Access

    Article

    Coexistence of regulatory B cells and regulatory T cells in tumor-infiltrating lymphocyte aggregates is a prognostic factor in patients with breast cancer

    Tumors can acquire tolerance to tumor immunity and develop enhanced proliferation. Regulatory B cells (Bregs), whose role in immune tolerance is similar to that of regulatory T cells (Tregs), appear to be invo...

    Emi Ishigami, Masahiro Sakakibara, Junta Sakakibara, Takahito Masuda in Breast Cancer (2019)